Efficacy of Ezetimibe/Simvastatin 10/40 mg Compared to Doubling the Dose of Low-, Medium- and High-Potency Statin Monotherapy in Patients with a Recent Coronary Event
| Autor: | K. Vandormael, R. Massaad, Philippe Brudi, J.P. Reckless, T. Pomykaj, D.P. Henry, S.T. Lim, Amy O. Johnson-Levonas |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
Simvastatin medicine.medical_specialty Statin medicine.drug_class Hypercholesterolemia Urology Ezetimibe Simvastatin Drug Combination Coronary Disease Ezetimibe medicine Humans Potency Pharmacology (medical) In patient Angina Unstable cardiovascular diseases Aged Apolipoproteins B Coronary event Dose-Response Relationship Drug business.industry Anticholesteremic Agents Cholesterol HDL nutritional and metabolic diseases Middle Aged Coronary heart disease Drug Combinations C-Reactive Protein Azetidines Female lipids (amino acids peptides and proteins) Ezetimibe/simvastatin Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Cardiology. 113:89-97 |
| ISSN: | 1421-9751 0008-6312 |
| Popis: | Objective: The aim of the study was to compare the efficacy/safety of doubling the dose of low-, medium- and high-potency statins on lipids/lipoproteins versus ezetimibe/simvastatin (EZE/SIMVA) 10/40 mg in patients with a recent coronary event. Methods: In this open-label study, patients were stratified by baseline statin therapy (low, medium and high potency) and randomized equally to statin dose doubling or EZE/SIMVA 10/40 mg for 12 weeks. Primary analysis concerned change in low-density lipoprotein cholesterol for the whole population. Treatment-by-stratum interaction evaluated the consistency of treatment effect across statin potency strata. Post hoc analysis of between-group efficacy within strata was performed using ANCOVA. Results: Within each stratum, EZE/SIMVA produced significantly greater reductions in low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B and non-high-density lipoprotein cholesterol (HDL-C) compared to statin doubling. Numerical trends toward smaller between-group reductions were observed with higher-potency statins and reached statistical significance for apolipoprotein B and non-HDL-C. No significant between-group differences in HDL-C and C-reactive protein were observed within each stratum. EZE/SIMVA produced larger reductions in triglycerides versus low-potency statin, whereas it was similarly effective compared with intermediate-/high-potency statins. The safety/tolerability profiles of the treatments were similar across the strata. Conclusions: EZE/SIMVA 10/40 mg produced greater improvements in lipids with a similar safety profile compared to doubling the dose of low-, medium- and high-potency statins. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|